169751-72-8

Basic information

• Product Name: PEG4-tert-butyl acetate
• Synonyms: PEG4-tert-butyl acetate;PEG5-tert-butyl acetate;PEG5-t-butyl acetate;HO-PEG4-CH2CO2t-Bu;Hydroxy-PEG4-t-butyl acetate;Hydroxy-PEG4-CH2CO2tBu;OH-PEG4-CH2COOH;Hydroxy-PEG4-CH2COOtBu
• CAS NO: 169751-72-8
• Molecular Formula: C₁₄H₂₈O₇
• Molecular Weight: 308.36792
• Mol File: 169751-72-8.mol

Chemical Properties

• Boiling Point: 393.1±32.0 °C(Predicted)
• Appearance: /
• Density: 1.077±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Soluble in Water, DMSO, DCM, DMF
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: PEG4-tert-butyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: PEG4-tert-butyl acetate(169751-72-8)
• EPA Substance Registry System: PEG4-tert-butyl acetate(169751-72-8)

Safety Data

• Hazardous Substances Data: 169751-72-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PEG4-tert-butyl acetate is used as a solubility enhancer for improving the aqueous solubility of hydrophobic drugs. The hydrophilic PEG spacer increases the drug's interaction with water, facilitating better dissolution and bioavailability.
Used in Chemical Synthesis:
In the field of chemical synthesis, PEG4-tert-butyl acetate serves as a versatile building block for the creation of various PEGylated compounds. The hydroxyl group allows for further functionalization, enabling the synthesis of a wide range of molecules with diverse applications.
Used in Drug Delivery Systems:
PEG4-tert-butyl acetate is utilized as a component in the design of drug delivery systems, such as nanoparticles or liposomes. The PEG spacer can improve the stability and circulation time of these systems in the body, while the t-butyl protected carboxyl group can be used for attaching drug molecules or targeting ligands.
Used in Bioconjugation:
In the field of bioconjugation, PEG4-tert-butyl acetate is employed as a linking agent to covalently attach biological molecules, such as proteins or peptides, to other molecules or surfaces. The hydroxyl group and t-butyl protected carboxyl group provide reactive sites for conjugation, while the PEG spacer can reduce potential immunogenicity or aggregation of the resulting bioconjugates.
Used in Surface Modification:
For surface modification applications, PEG4-tert-butyl acetate is used as a coating agent to introduce hydrophilic and non-fouling properties to various surfaces, such as medical devices or sensors. The PEG spacer helps to resist protein adsorption and cell adhesion, while the t-butyl protected carboxyl group can be used to anchor the molecule to the surface.

Upstream product

• 112-60-7 Tetraethylene glycol 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 169751-71-7 [2-(2-{2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid tert-butyl ester 
• 134179-40-1 tetraethyleneglycol mono(tert-butyldimethylsilyl)ether 

Downstream Products

• 169751-73-9 tert-butyl 2-[2-[2-[2-[2-(p-tolylsulfonyloxy)ethoxy]ethoxy]ethoxy]ethoxy]acetate 

Relevant articles and documents

Protein degradation through covalent inhibitor-based PROTACs

Tremendous advancements in proteolysis targeting chimera (PROTAC) technology have been made in recent years. However, whether a covalent inhibitor-based PROTAC can be developed remains controversial. Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.

RAF-DEGRADING CONJUGATE COMPOUNDS

The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF- Degrading Conjugate Compound.

Identification and Characterization of von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality to become a differentiated and therapeutic reality is strong, such that both academic and pharmaceutical institutions are now entering this interesting area of research. In this article, we describe a broadly applicable process for identifying degrader hits based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) and have generalized the key structural elements associated with degradation activities. Compound 3i is a potent hit (TBK1 DC50 = 12 nM, Dmax = 96%) with excellent selectivity against a related kinase IKK?, which was further used as a chemical tool to assess TBK1 as a target in mutant K-Ras cancer cells.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE

The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

COMPOUNDS FOR THE MODULATION OF RIP2 KINASE ACTIVITY

The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.

Synthese von massgeschneiderten Glycokonjugaten, die AT-III-vermittelt die Blutgerinnungsfaktoren Xa und Thrombin inhibieren

Keywords: Antithrombotica; Enzyminhibitoren; Heparin